{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:41:11Z","timestamp":1759657271089,"version":"build-2065373602"},"reference-count":0,"publisher":"Biomedical Informatics","issue":"09","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bioinformation"],"published-print":{"date-parts":[[2025,9,30]]},"abstract":"<jats:p>Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in individuals with type 2 diabetes mellitus (T2DM). Antidiabetic agents, sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) have demonstrated cardiovascular benefits, though direct comparative data are limited. This retrospective cohort study analysed records of 300 T2DM patients treated between January 2021 and December 2023 at a tertiary care centre. Patients were divided into two groups: Group A (n=150) received SGLT2i (empagliflozin or dapagliflozin), and Group B (n=150) received GLP-1 RA (liraglutide or semaglutide). Major adverse cardiovascular events (MACE), including myocardial infarction, stroke, and cardiovascular death, were tracked over 24 months. Group A showed a lower incidence of MACE (11.3%) compared to Group B (15.3%), though the difference was not statistically significant (p=0.182). Kaplan-Meier curves indicated slightly better event-free survival in the SGLT2i group. Haemoglobin A1c reduction was similar between the groups (1.2% vs. 1.3%, p=0.456), while hospitalization for heart failure was significantly lower in the SGLT2i group (6.0% vs. 10.6%, p=0.048). Thus, we show that both SGLT2 inhibitors and GLP-1 receptor agonists offer cardiovascular protection in T2DM, with SGLT2i providing a modest advantage in reducing MACE and a significant benefit in lowering heart failure hospitalizations.<\/jats:p>","DOI":"10.6026\/973206300213000","type":"journal-article","created":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:09:11Z","timestamp":1759655351000},"page":"3000-3003","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of cardiovascular event reduction with SGLT2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes mellitus"],"prefix":"10.6026","volume":"21","author":[{"name":"Department of Internal Medicine, Columbus Regional Hospital, 2400 17th St, Columbus, Indiana, United States of America","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijaya Krishna Prasad","family":"Vudathaneni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swetha Bharathi","family":"Nadella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Internal Medicine, Columbus Regional Hospital, 2400 17th St, Columbus, Indiana, United States of America","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalikrishna Varaprasad","family":"Movva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Anaesthesiology, Anaesthetics, Principal House Officer, Mackay Base Hospital, Mackay, Queensland, Australia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phanindra","family":"Dulipala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Community Medicine, Katuri Medical College and Hospital, Guntur, Andhra Pradesh, India","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramanarayana","family":"Boyapati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Periodontology, Sibar Institute of Dental Sciences, Takkellapadu, Guntur, Andhra Pradesh, India","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4070","published-online":{"date-parts":[[2025,9,30]]},"container-title":["Bioinformation"],"original-title":[],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:09:12Z","timestamp":1759655352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bioinformation.net\/021\/973206300213000.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":0,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2025,9,30]]},"published-print":{"date-parts":[[2025,9,30]]}},"URL":"https:\/\/doi.org\/10.6026\/973206300213000","relation":{},"ISSN":["0973-8894","0973-2063"],"issn-type":[{"value":"0973-8894","type":"print"},{"value":"0973-2063","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]}}}